{"name":"AUVA Traumazentrum Vienna Site UKH Meidling","slug":"auva-traumazentrum-vienna-site-ukh-meidling","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Intravenous Infusion of Aclasta®","genericName":"Intravenous Infusion of Aclasta®","slug":"intravenous-infusion-of-aclasta","indication":"Treatment of osteoporosis in postmenopausal women","status":"phase_2"}]}],"pipeline":[{"name":"Intravenous Infusion of Aclasta®","genericName":"Intravenous Infusion of Aclasta®","slug":"intravenous-infusion-of-aclasta","phase":"phase_2","mechanism":"Bisphosphonate that inhibits osteoclast-mediated bone resorption","indications":["Treatment of osteoporosis in postmenopausal women","Treatment of bone metastases in patients with breast cancer or multiple myeloma"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}